Moderna stock has faced heavy pressure from negative headlines, regulatory setbacks and political uncertainty. See why I ...

Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 3.6% in the morning session after JPMorgan added the stock to its ...

The capped upside and unlimited downside risk make MRNY unattractive unless Moderna's share price stabilizes and recovers ...

Scientific experts are concerned about what role vaccines will play in US public health strategy under the Trump ...

While US exceptionalism may have lost some of its shine, it is worth remembering that the US stock market remains home to many world-leading companies.

Nvidia's price target was raised by Loop Capital, which said the chipmaker's market cap could reach $6 trillion. U.S.

Merck MRK announced a definitive agreement to acquire Verona Pharma VRNA for approximately $10 billion. The deal will add ...

due to strong earnings and expected future expansion. The trust combines the best ideas from both value and growth managers within a single strategy, with the flexibility to shift the portfolio ...

The U.S. Food and Drug Administration has granted full approval for Moderna's COVID-19 vaccine, Spikevax, in children aged 6 ...

Future Outlook and Challenges As Moderna looks to the future, several factors will be critical in determining its success.

Moderna (NasdaqGS:MRNA) underwent significant index changes, adding to the Russell Midcap indices while exiting the Russell Top 200 indices. This reclassification might have signaled a shift in ...